Profile cover photo
Profile photo
OIS: Ophthalmology Innovation & Investment
559 followers -
OIS facilitates meaningful interactions and partnerships between investors, entrepreneurs, industry executives, and physicians who drive ophthalmic innovation
OIS facilitates meaningful interactions and partnerships between investors, entrepreneurs, industry executives, and physicians who drive ophthalmic innovation

559 followers
About
OIS: Ophthalmology Innovation & Investment's posts

Post has attachment
Dave Van Meter, president and CEO of Ivantis, updated OIS@ASCRS attendees on the Hydrus Microstent. Ivantis, like Glaukos, is focused on using the Schlemm’s canal as the point of outflow.

To learn more, watch this OIS@ASCRS Company Presentation:

Post has attachment
Applied Genetic Technologies Corporation (AGTC) finds itself well positioned to fund the programs along with five others it has in the works as its cash position is about 50% ahead of where the firm expected to be at mid-year.

Learn more:

Post has attachment
Bob Butchofsky, CEO of Mati Therapeutics, updated OIS@ASCRS on the company’s punctal plug delivery system, introducing 12-week data from a Phase II multicenter clinical trial for the treatment of glaucoma.

To learn more, watch this OIS@ASCRS Company Presentation:

Post has attachment
In this OIS Podcast, Jerry St. Peter, VP & head, ophthalmic business, says the ophthalmology newcomer is making great progress in building a broad pipeline to treat eye disease including dry eye and ocular pain.

Listen here to learn more:

Post has attachment
John Hendrick, president and CEO of Mynosys Cellular Devices, reported strong progress for Zepto, a disposable capsulotomy device.

To learn more, watch this OIS@ASCRS Company Presentation:

Post has attachment
Jonathan Talamo, MD, chief medical officer at Ocular Therapeutix updated OIS@ASCRS attendees on the clinical progress of Dextenza, which is the subject of an NDA being reviewed by the FDA, and is a treatment for post-surgical pain and inflammation.

Post has attachment
Gary Wörtz, MD, chief medical officer of Omega Opthalmics, allowed OIS attendees to see the first public implantation of his company’s Omega Gemini Refractive Capsule.

To learn more, watch this OIS@ASCRS Company Presentation:

Post has attachment
Barry Cheskin, Co-founder, President, & CEO, delivered early results on the release of FluidVision 2020 into the clinic. The company reports 24 successful surgeries to date.

To learn more, watch this OIS@ASCRS Company Presentation:

Post has attachment
Board member Gerd Auffarth, MD, shared his unique perspective on Presbia’s Flexivue Microlens designed to eliminate the need for reading glasses.

To learn more, watch this OIS@ASCRS Company Showcase:

Post has attachment
Jim McCollum, Co-founder & Board member, introduced LiquidVision, an eye drop regimen that might correct presbyopia.

To learn more, watch this OIS@ASCRS Company Showcase:
Wait while more posts are being loaded